CybinCYBN
About: Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions.
Employees: 50
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
125% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 8
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
18% more funds holding
Funds holding: 45 [Q3] → 53 (+8) [Q4]
1.75% less ownership
Funds ownership: 36.34% [Q3] → 34.6% (-1.75%) [Q4]
6% less capital invested
Capital invested by funds: $64.6M [Q3] → $61M (-$3.56M) [Q4]
86% less call options, than puts
Call options by funds: $1.87M | Put options by funds: $13.1M
100% less funds holding in top 10
Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Guggenheim Eddie Hickman 33% 1-year accuracy 3 / 9 met price target | 376%upside $35 | Buy Initiated | 13 Mar 2025 |
HC Wainwright & Co. Patrick Trucchio 15% 1-year accuracy 28 / 186 met price target | 1,941%upside $150 | Buy Maintained | 13 Feb 2025 |
Canaccord Genuity Sumant Kulkarni 7% 1-year accuracy 2 / 29 met price target | 893%upside $73 | Buy Maintained | 12 Feb 2025 |
Financial journalist opinion









